Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Approved by the FDA in 2017, Verzenio is the first CDK4/6 inhibitor approved in combination with fulvestrant for treating women with HR+, HER2- breast cancer
The only notification I received was a delivery confirmation email, and it arrived two full days after the package was already on my doorstep, with a tracking number attached
No symptoms
Investment analysts expect production costs of orforglipron to be 30 to 50% lower than injectables
Novo Nordisk let a key patent lapse
US$ 21.97
US$ 20.06
US$ 29.07
US$ 29.45
US$ 28.98
